¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Bacterial infection of unspecified site"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® infection ÇÑ±Û °¨¿°
¼³¸í   
  º´¿ø¹Ì»ý¹°ÀÌ »ç¶÷À̳ª µ¿¹° ¶Ç´Â ½Ä¹°ÀÇ Á¶Á÷. Ã¼¾×-Ç¥¸é¿¡ Á¤ÂøÇÏ¿© Áõ½ÄÇϴ »óÅÂ. ÀÌ °æ¿ì µ¿¹° ¶Ç´Â ÀÎü¿¡ ¿©·¯ °¡Áö Áõ»ó, Áï Áúº´À» ÀÏÀ¸Å°´Â °æ¿ì¿Í ÀÏÀ¸Å°Áö ¾Ê´Â °æ¿ì°¡ ÀÖ´Ù. ¿¹¸¦ µé¸é, ÀϺ»³ú¿°¹ÙÀÌ·¯½º°¡ ÀÎü¿¡ Ä§ÀÔÇÏ¿© Ã¼³»¿¡ Áõ½ÄÇϸ頾 »ç¶÷¿¡°Ô´Â °í¿­-µÎÅë-ÀǽÄÀå¾Ö-°æ·Ã µîÀÇ Áõ»óÀÌ ÀϾ ¹ßº´À» ¾ËÁö¸¸, ´ë´Ù¼öÀÇ »ç¶÷Àº Ã¼³»¿¡¼­ ¹ÙÀÌ·¯½º°¡ Áõ½ÄÇÏ´õ¶óµµ Áõ¼¼ÀÇ Á¤µµ°¡ ³·°í ¹ß¿­À̳ª ±× ¹ÛÀÇ Áõ¼¼µµ ¾ø¾î °¨¿°À» ¸ð¸¥´Ù. À̿͠°°ÀÌ º´¿ø¹Ì»ý¹°Àº ÀÎü¿¡ °¨¿°µÇ´õ¶óµµ ¹ßº´Çϴ °æ¿ì¿Í ÇÏÁö ¾Ê´Â °æ¿ì°¡ ÀÖ´Ù. ÀüÀÚ¸¦ Áõ»ó°¨¿°, ÈÄÀÚ¸¦ ¹«Áõ»ó°¨¿°À̶ó ÇÑ´Ù. °¨¿°ÀÇ ±Ù¿øÀÌ µÇ´Â È¯ÀÚ-º¸±ÕÀÚ-°¨¿°µ¿¹°-¸Å°³µ¿¹°-º´¿øÃ¼¸¦ Æ÷ÇÔÇÑ ¹è¼³¹° ¹× ±×¿¡ ÀÇÇØ °¨¿°µÈ °ÍÀ» °¨¿°¿øÀ̶ó Çϰí, ÀÌ·¯ÇÑ °¨¿°¿ø¿¡¼­ Á÷Á¢ ¶Ç´Â °£Á¢À¸·Î »ýü¿¡ º´¿øÃ¼°¡ Ä§ÀÔÇϴ °æ·Î¸¦ °¨¿°°æ·Î¶ó ÇÑ´Ù. °¨¿°°æ·Î¿¡´Â °ø±â°¨¿°-Á¢Ã˰¨¿°-°æ±¸°¨¿°-°æÇǰ¨¿° µîÀÌ ÀÖ´Ù. ¶ÇÇÑ °¨¿°ÁõÀº Àü¿°¼º°ú ºñÀü¿°¼ºÀÇ µÎ °¡Áö·Î ³ª´­ ¼ö ÀÖ´Ù. ÀüÀڴ Áúº´ÀÇ °æ°ú Áß¿¡(¶§·Î´Â Àẹ±â³ª È¸º¹±â¿¡) °¨¿°ÇÑ »ýüÀÇ ºÐºñ¹° ¶Ç´Â ¹è¼³¹°°ú ÇÔ²² º´¿øÃ¼°¡ ³ª¿Í¼­ Á¢ÃË ¶Ç´Â ¸Å°³¿¡ ÀÇÇØ ´Ù¸¥ °³Ã¼¸¦ °¨¿°½Ã۴ °æ¿ì¸¦ ¸»ÇÑ´Ù. ¸¶¸¶-µðÇÁÅ׸®¾Æ-¼ºÈ«¿­-Æä½ºÆ®-ÄÝ·¹¶ó-ÀÌÁú µîÀÌ ÀÌ¿¡ ¼ÓÇÑ´Ù. ÈÄÀڴ º´¿øÃ¼°¡ °¨¿°ÇÑ »ýü¿¡¼­ ¹è¼³µÇÁö ¾Ê°Å³ª ¹è¼³µÇ´õ¶óµµ ´Ù¸¥ °³Ã¼¿¡´Â °¨¿°À» ÀÏÀ¸Å°Áö ¾Ê´Â °ÍÀ¸·Î ¿©±â¿¡´Â ÆÄ»ódz-¸»¶ó¸®¾Æ-¹ßÁøÆ¼Çª½º-»êÈÄ¿­ µîÀÌ ÀÖ´Ù.
¿µ¹® droplet infection ÇÑ±Û ºñ¸»°¨¿°, ÀÛÀº¹æ¿ï°¨¿°
¼³¸í   
  º¸±ÕÀÚ³ª Áõ»óÀÌ Àִ ȯÀڠȤÀº À̹̠°¨¿°µÇ¾î Àִ »ç¶÷ÀǠȣÈí¿¡¼­ ³ª¿Â Á÷°æ 10¸¶ÀÌÅ©·Ð ¶Ç´Â ±× ÀÌÇÏÀÇ ¾×üÀÔÀÚ¿¡ ºÎÀ¯Çϰí Àִ º´¿øÃ¼ÀÇ ÈíÀÔ¿¡ ÀÇÇѠȣÈí±â°¨¿°À» À̸¥´Ù. ÀÎÇ÷翣ÀÚ³ª Æíµµ¿°°ú °°À̠ȯÀÚ°¡ ±âħÀ» Çϰųª ´ëÈ­ µµÁß¿¡ ÀÚÀßÇÑ ºñ¸»°ú ÇÔ²² º´¿ø±ÕÀÌ °ø±â¿Í ÇÔ²² º´¿ø±ÕÀÌ ¹æÃâµÇ¾î °ø±â¿Í ÇÔ²² È£Èí±â·Î ÈíÀÔµÊÀ¸·Î½á °¨¿°µÇ´Â °ÍÀ» ¸»ÇÑ´Ù. °áÇÙ-À¯Ç༺°¨±â-¹éÀÏÇØ-µðÇÁÅ׸®¾Æ-Æó·Å µîÀÌ ÀÌ¿¡ ÀÇÇÏ¿© ÀüÆÄµÈ´Ù.
¿µ¹® wound infection ÇÑ±Û »ó󰨿°
¼³¸í   
  Àý¼Õ µîÀÇ ±â°èÀû »óÇØ, ÀÎÀ§Àû ºÎ»ó ¶Ç´Â Å¸±ÕÀǠħÀÔ¿¡ ÀÇÇØ »óó³­ Á¶Á÷¿¡¼­ Ä§ÀÔÇÏ¿© °¨¿°½Ã۴ °Í.
¿µ¹® secondary infection ÇÑ±Û ÀÌÂ÷°¨¿°
¼³¸í   
  ¾î¶² º´¿øÃ¼ÀÇ °¨¿°¿¡ ÀÇÇÏ¿© º»ÀÎÀÇ ÀúÇ×·ÂÀÌ ¾àÇØÁ³À» ¶§ ¸öÀÇ ´Ù¸¥ ºÎÀ§·Î ÀüÀÌÇÏ¿© ´Ù½Ã °¨¿°À» ÀÏÀ¸Å°´Â °Í. º´¿øÃ¼°¡ ÀÎü¿¡ Ä§ÀÔÇÏ¿© Æ¯Á¤ÇÑ ±â°üÀ̳ª Á¶Á÷¿¡¼­ º´¿øÃ¼°¡ Áõ½ÄÇϰí, ±×°÷¿¡ Æ¯À¯ÀÇ º´Å͸¦ ÀÏÀ¸Å°´Â °ÍÀÌ 1Â÷°¨¿° ¶Ç´Â Ãʰ¨¿°ÀÌ´Ù. ÀÌ 1Â÷°¨¿°ÀÇ º´ÅÍÀÇ º´¿øÃ¼°¡ Ç÷°ü-¸²ÇÁ°ü-±â°ü-¼ÒÈ­°ü-¿ä°ü µîÀÇ ±æÀ» µû¶ó °°Àº ±â°üÀÇ ´Ù¸¥ ºÎÀ§³ª ´Ù¸¥ ±â°üÀ¸·Î ¿î¹ÝµÇ¾î °¨¿°À» ÀÏÀ¸Å²´Ù. µû¶ó¼­ 1Â÷°¨¿°¿¡ ÀÇÇÏ¿© ÃæºÐÇÑ ¸é¿ªÀÌ µÉ °æ¿ì¿¡´Â 2Â÷°¨¿°ÀÌ ÀϾÁö ¾Ê´Â´Ù. ¿¹¸¦ µé¾î, À¯Ç༺ °¨±â¿¡ °É·ÈÀ» ¶§ ¼¼±Õ¿¡ ÀÇÇÑ Æó·ÅÀÌ µÚµû¸£´Â °æ¿ì¸¦ À̸¥´Ù. Æó·Å±Õ, È­³ó¾Ë±Õ, ´ëÀå±Õ µûÀ§°¡ ÀÖ´Ù. 
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • donor site
    Á¦°øºÎÀ§, °ø¿©ºÎÀ§
  • fragile site
    Ãë¾àºÎÀ§
  • ligand binding site
    ¸®°£µå°áÇÕºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • site
    ºÎÀ§
  • telomeric site
    ³¡ºÐÀýºÎÀ§
  • bacterial
    ¼¼±Õ-
  • bacterial antagonism
    ¼¼±Õ´ëÇ×ÀÛ¿ë, ¼¼±Õ¸Â¹öÆÀÀÛ¿ë
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bacterial colony
    ¼¼±ÕÁý¶ô
  • bacterial translocation
    ¼¼±Õ ÀüÀ§
  • bacterial vaginosis
    ¼¼±ÕÁúÁõ
  • site
    ºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • infection cycle
    °¨¿°°í¸®, °¨¿°»ç
  • infection
    °¨¿°
  • abortive infection
    ºÒ¹ß°¨¿°, ºÒÇö°¨¿°
  • fetal infection
    žư¨¿°
  • latent infection
    Àẹ°¨¿°
  • localized infection
    ±¹¼Ò°¨¿°
  • natural infection
    ÀÚ¿¬°¨¿°
  • neonatal infection
    °«³­¾Ö°¨¿°, ½Å»ý¾Æ°¨¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bacterial antagonism
    ¼¼±Õ¸Â¹öÆÀÀÛ¿ë
  • bacterial
    ¼¼±Õ-
  • bacterial colony
    ¼¼±ÕÁý¶ô
  • bacterial conjugation
    ¼¼±ÕÁ¢ÇÕ
  • bacterial cytology
    ¼¼±Õ¼¼Æ÷ÇÐ
  • bacterial decomposition
    ¼¼±ÕºÐÇØ
  • bacterial disease
    ¼¼±Õº´
  • bacterial exotoxin
    ¼¼±Õ¿Üµ¶¼Ò
  • bacterial flora
    ¼¼±Õ¹«¸®
  • bacterial shock
    ¼¼±Õ¼îÅ©
  • bacterial species
    ¼¼±ÕÁ¾
  • bacterial strain
    ±ÕÁÖ
  • bacterial growth rate
    ¼¼±ÕÁõ½Ä·ü
  • bacterial interference therapy
    ¼¼±Õ°£¼·¿ä¹ý
  • total bacterial count
    Ãѱռö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • SBE= subacute bacterial endocarditis
    ¾Æ±Þ¼º ¼¼±Õ¼º ½É³»¸·¿°.
  • acute bacterial arthritis
    ±Þ¼º ¼¼±Õ¼º °üÀý¿°(Ðáàõá¬Ð¶àõÎ¼ï½æú).
  • acute bacterial arthritis
    ±Þ¼º ¼¼±Õ¼º °üÀý¿°(¡­á¬Ð¶àõÎ¼ï½æú).
  • acute bacterial endocarditis
    ±Þ¼º ¼¼±Õ¼º ½É³»¸·¿°(¡­á¬Ð¶àõãýҮدæú).
  • gelatinoid plaque =dental p., bacterial p.
    Ä¡¾Æ¼¼±Õ¸·(öÍä³á¬Ð¶Ø¯).
  • genetics, bacterial
    ¼¼±ÕÀ¯ÀüÇÐ
  • plasmid, bacterial
    ¼¼±ÕÇö󽺹̵å
  • preputial bacterial colonization
    Æ÷ÇǼ¼±ÕÀüÁö±º°Å
  • recurrent bacterial meningitis
    Àç¹ß¼º ¼¼±Õ¼º ¼ö¸·¿°(î¢Û¡àõá¬Ð¶àõâÐØ¯æú).
  • recurrent bacterial meningitis
    Àç¹ß¼º ¼¼±Õ¼º ¼ö¸·¿°(î¢Û¡àõá¬Ð¶àõâÐØ¯æú)
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bacterial infection
    ¼¼±Õ(¼º)°¨¿°.
  • secondary bacterial infection
    ÀÌÂ÷¼¼±Õ°¨¿°
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • binding site
    °áÇÕºÎÀ§.
  • binding site
    °á ÇÕºÎÀ§.
  • combining site
    °áÇÕºÎ(Ì¿ùêÝ»).
  • combining site
    °áÇÕºÎÀ§
  • combining site of antibody
    Ç×üÀÇ °áÇÕºÎ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Abnormality by infection
    °¨¿°±âÇü
    [¿¾ ¿ë¾î] °¨¿°ºñÁ¤»ó
  • Variations of site
    À§Ä¡º¯ÀÌ
    [¿¾ ¿ë¾î] À§Ä¡ÀÌ»ó
  • Corporal site
    ÀڱøöÅëÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃüºÎ
  • Absorption site
    Èí¼öÁ¡
    [¿¾ ¿ë¾î] Èí¼öÃÊÁ¡
  • Fundic site
    ÀڱùٴÚÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃÀúºÎ
  • Definitive site
    Âø»óÀÚ¸®
    [¿¾ ¿ë¾î] À§Ä¡¼±Á¤
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • congenital infection
    ¼±Ãµ°¨¿°
  • ectopic infection
    À̼Ұ¨¿°
  • helminthic infection
    ¿¬Ãæ°¨¿°
  • household infection
    Áý¾È°¨¿°
  • indigenous infection
    ÅäÂø°¨¿°
  • infection intensity
    °¨¿°°­µµ
  • latent infection
    Àẹ°¨¿°
  • Leishmania mexicana mexicana infection
    ¸ß½ÃÄÚ¸®½´¸¸Æí¸ðÃæÁõ
  • mosquito borne infection
    ¸ð±â¸Å°³°¨¿°
  • opportunistic infection
    ±âȸ°¨¿°
  • oral infection
    °æ±¸°¨¿°
  • percutaneous infection
    °æÇǰ¨¿°
  • primary infection
    ÀÏÂ÷°¨¿°
  • protozoan infection
    ¿øÃæ°¨¿°
  • secondary infection
    ÀÌÂ÷°¨¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bacterial ferredoxin
    ±Õ(ж)Æä·¹µ¶½Å
  • A-site-P-site moel
    AÀÚ¸® PÀÚ¸® ¸ðµ¨
  • abortive infection
    ¹Ì¼÷°¨¿° (Ú±âÙÊïæø)
  • abortive infection
    ºÎÀü°¨¿° (ÜôîïÊïæø)
  • abortive infection
    ºÒ¿Ï°¨¿° (ÝÕèÇÊïæø)
  • cross-infection
    ±³Â÷°¨¿°(Îßó©Êïæø)
  • endosymbiotic infection
    ³»°ø»ý °¨¿° (Ò®ÍìßæÊïæø)
  • latent infection
    Àẹ°¨¿°(íÖÜÑÊïæø)
  • localized infection
    ±¹¼Ò°¨¿°(ÏÑá¶Êïæø)
  • productive infection
    »ý»ê °¨¿°(ßæß§Êïæø)
  • acceptor site
    ¼ö¿ëºÎÀ§ (â¥é»Ý»êÈ)
  • active site
    Ȱ¼º(üÀàõ)ÀÚ¸®
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • alternate-site model
    ±³´ëºÎÀ§(ÎßÓÛÝ»êÈ)¸ðÅÚ
  • amino acid attachement site
    ¾Æ¹Ì³ë»ê(ß«) ºÎÂø(ݾó·)ÀÚ¸®
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • site
    À§Ä¡,»çÀÌÆ®
  • web site
    À¥½ÎÀÌÆ®
  • air borne infection
    °ø±â°¨¿°, ÈíÀÔ°¨¿°
  • contagious infection
    Á¢Ã˰¨¿°, Á¢ÃËÀü¿°
  • descending infection
    ÇÏÇà°¨¿°
  • enteral infection
    Àå°ü°¨¿°
  • fungal infection
    °õÆÎÀ̰¨¿°, Áø±Õ°¨¿°
  • generalized infection
    Àü½Å°¨¿°
  • granulomatous infection
    À°¾ÆÁ¾¼º°¨¿°Áõ
  • hemolytic streptococcal infection
    ¿ëÇ÷¼º¿¬¼â±¸±Õ°¨¿°
  • hospital infection
    ¿ø³»°¨¿°, º´¿ø°¨¿°
  • infection
    °¨¿°, Àü¿°
  • meningococcal infection
    ¼ö¸·±¸±Õ°¨¿°(Áõ)
  • mixed infection
    È¥ÇÕ°¨¿°
  • periapical infection
    ±Ù÷ÁÖÀ§°¨¿°(Áõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FS factor of safety; Fanconi syndrome; Felty syndrome; fibromyalgia syndrome; field stimulation; Fisher...
STANDOUT soft thresholding and depth cueing of unspecified techniques
URD unspecified respiratory disease; upper respiratory disease
BAC bacterial adherent colony; bacterial antigen complex; blood alcohol concentration; British Associati...
SSI segmental sequential irradiation; shoulder subluxation inhibition; small-scale integration; Social S...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SBI serious bacterial infection
Site 1 site
ESI Exit-site infection
SSI Surgical Site Infection
ABM Acute bacterial meningitis
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • A49
    Bacterial infection of unspecified site
    »ó¼¼ºÒ¸í ºÎÀ§ÀÇ ¼¼±Õ¼º °¨¿°
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • unspecified
    ºñƯÀ̼º
    ´Ù¸¥ °ÍÇÏ°í¸¸ Ưº°È÷ °áÇÕÀ» ÇÑ´ÙµçÁö ¹ÝÀÀÇϴ ƯÀ̼ºÀÌ ¾ø´Â.
  • bacterial infection
    ¼¼±Õ °¨¿°, ¼¼±Õ¼º °¨¿°, ¹ÚÅ׸®¾Æ °¨¿°
    ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°. °áÇÙ±Õ°ú °°ÀÌ ¸¸¼º À°¾ÆÁ¾¼º ¿°ÁõÀ» ÀÏÀ¸Å°´Â ÀϺÎÀÇ ¼¼±ÕÀ» Á¦¿ÜÇϰí´Â ´ëºÎºÐ È­³ó¼º ¿°ÁõÀ» ÀÏÀ¸Å°¸ç µå¹°°Ô °æ¸·¿Ü ¶Ç´Â °æ¸·ÇÏ ³ó¾çÀ» Çü¼ºÇϱ⵵ ÇÏÁö¸¸ ´ë°³ È­³ó¼º ¼ö¸·¿°, ±¹¼ÒÀû ³ú¿°, ³ú ³ó¾çÀ» Çü¼ºÇÑ´Ù.
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • antigen combining site
    Ç׿ø °áÇÕºÎ
  • antigen recognition site
    Ç׿ø ½Äº°ºÎ
  • cleavage site
    ºÐ¿­ ºÎÀ§
  • combining site
    °áÇÕºÎ
  • electrophilic site
    Ä£ÀüÀÚ ¹ÝÀÀ¹°
  • molecular site
    ºÐÀÚ À§
  • receptor site
    ¼ö¿ëü ºÎÀ§, ¼ö¿ëºÎ
    ƯÁ¤ÇÑ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ÃÊ·¡ÇÏ´Â ºÐÀÚ °áÇÕÀÌ ÀϾ´Â ƯÁ¤ ºÎÀ§.
  • recognition site
    ÀÎ½Ä ºÎÀ§
  • site
    À§Ä¡, »çÀÌÆ®
  • site of pain modulation
    µ¿Åë Á¶Àý ºÎÀ§
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
bacterial infection <microbiology> Bacteria are group of micro-organisms that are a single cell approximately 1 micron in transverse diameter. Some bacteria cause disease in man, requiring treatment with an antibiotic.
(27 Sep 1997)
acceptor site The ribosomal binding site for the aminoacyl-tRNA during protein synthesis.
(05 Mar 2000)
acceptor splicing site Boundary between the right end of an intron and the left end of the adjacent exon.
Synonym: acceptor splicing site.
(05 Mar 2000)
active site <chemistry> A specific region of an enzyme where a substrate binds and catalysis takes place (binding site).
(06 May 1997)
allosteric site A specific site on a multi-subunit enzyme or other protein that is not the substrate binding site, but that when reversibly bound by an effector, induces a conformational change in the protein, altering its catalytic or binding properties.
(12 Dec 1998)
amidation site <molecular biology> A C terminus consensus sequence, required for C terminus amidation of peptides. Consensus is glycine, followed by 2 basic amino acids (arg or lys).
(18 Nov 1997)
antibody combining site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-combining site See: paratope.
(05 Mar 2000)
apurinic site <molecular biology> Sites in DNA from which purines have been lost by cleavage of the deoxy ribose N glycosidic linkage.
(18 Nov 1997)
apyrimidinic site <molecular biology> A site on DNA where a base is missing, in this case a pyrimidine (either cytosine or thymine), but the phosphodiester backbone is still intact.
Compare: apurinic site.
(09 Oct 1997)
ATT site <molecular biology> A site on the chromosome of the bacteria E. Coli where the lambda bacteriophage can insert its genome (all of its DNA) so that it can lie dormant and have its DNA reproduced whenever the bacterium reproduces for as long as the bacterium remains healthy (that is, so that it becomes lysogenic).
(09 Oct 1997)
gaylus-site <chemical> A yellowish white, translucent mineral, consisting of the carbonates of lime and soda, with water.
Origin: Named after Gay-Lussac, the French chemist.
(20 Mar 1998)
receptor site Point of attachment of viruses, hormones, or other activators to cell membranes.
(05 Mar 2000)
catalytic site <chemistry> The site on an enzyme where the substrate or substrates (the reactants of a chemical or biochemical reaction) attach in order to convert to the product or products of the reaction, at a much higher speed than the substrate would need to convert to the product alone.
(16 Mar 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • unspecified
    Ư±â
  • bacterial
    ¼¼±Õ¿¡ ÀÇÇÑ
  • bacterial
    ¹ÚÅ׸®¾Æ(¼¼±Õ)ÀÇ
  • infection
    ¿µÇâ; Àü¿°º´
  • droplet infection
    (ÀÇ)ºñ¸» °¨¿°
  • focal infection
    º´¼Ò°¨¿°
  • infection
    (º´µ¶ÀÇ)°ø±âÀü¿°;°¨¿°(cf.CONTAFION)(µµ´öÀûÀ¸·Î)³ª»Û °¨È­(¿µÇâ);¿À¿°(CONTAMINATION)Àü¿°º´;°¨¿°Áõ
  • infection point
    º¯°îÁ¡
  • site
    À§Ä¡
  • caravan park (site)
    À̵¿ÁÖÅÃ(Æ®·¹ÀÏ·¯) ÁÖÂ÷Àå
  • ceru(s)site
    ¹é¿¬±¤
  • county seat (site)
    ±ºÃ» ¼ÒÀçÁö;±ºÀÇÇàÁ¤ Áß½ÉÁö
  • launching site
    ¹ß»ç±âÁö
  • receptor site
    ¼¼Æ÷³» ¼ö¿ë ¿µ¿ª
  • restriction site
    Á¦ÇÑ ºÎÀ§(Á¦ÇÑ È¿¼Ò°¡ Àý´ÜÇÏ´Â µÎ ÁÙ »ç½½ DNA»óÀÇ ºÎÀ§)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á